Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least in the short term, this cannabinoid combination did not improve objective sleep duration. These findings highlight that popular perceptions of cannabis as a straightforward sleep aid may not align with measurable EEG-based outcomes, and patients should be counseled that subjective sleep improvement does not always reflect better sleep architecture. Larger controlled trials are needed before clinical recommendations can be made about cannabinoid dosing for insomnia.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination affects sleep architecture and cortical activity in clinically diagnosed insomnia patients, filling a critical evidence gap given widespread use of cannabinoids for sleep without robust polysomnographic data. The detailed neurophysiological assessment enables clinicians to understand not only whether cannabinoids improve sleep initiation or maintenance, but also their effects on sleep stage distribution and next-day cognitive function, informing evidence-based prescribing decisions in patients for whom conventional hypnotics are ineffective or contraindicated.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides valuable objective neurophysiological data on acute THC/CBD effects in insomnia patients, moving beyond subjective reports to quantify sleep architecture and EEG changes. However, the small sample size (n=20), single-dose design, and lack of detail on baseline sleep severity, prior cannabis exposure, and potential sex-based differences limit generalizability, particularly given the female predominance in the cohort. The fixed 10:20 THC-to-CBD ratio tested here may not reflect optimal dosing for individual patients, and the absence of next-day cognitive or driving safety data is a notable gap for clinical practice. Despite these limitations, if the study demonstrates improvements in sleep continuity or slow-wave sleep without significant morning impairment, it could inform a conservative trial in carefully selected, cannabis-naive insomnia patients who have failed conventional therapies. Clinicians should view this as preliminary evidence supporting further rigorous research rather than a rationale to broadly prescribe cannabinoids for sleep, and